The Food and Drug Administration has approved an autoinjector that lets patients give themselves a full intravenous-equivalent dose of the most widely used loop diuretic at home, in under 10 seconds.
MannKind Corporation announced the approval of Furoscix ReadyFlow, a furosemide injection given under the skin of the abdomen, for the treatment of edema in adults with heart failure or chronic kidney disease. The company expects it to reach the market by the end of August.
The clinical target is narrow and specific. It is the patient whose oral diuretic has stopped keeping up with fluid buildup, who is gaining weight and swelling and short of breath, and whose only current option for a stronger dose is a hospital, an emergency department or an infusion center.
Whether an injector actually keeps those people out of hospitals is a separate question, and the approval does not answer it.
What Was Approved and How It Differs
Furosemide, familiar to most patients as Lasix, is the backbone of congestion management in heart failure. Taken by mouth, it is absorbed erratically, and absorption gets worse during an acute episode of fluid overload, which is precisely when it is needed most. That is why guidelines push toward intravenous dosing when congestion becomes significant, and why that usually means a facility.
A subcutaneous version already existed. The Furoscix On-body Infusor, a wearable pump approved for heart failure edema in 2022 and extended to chronic kidney disease in 2025, delivers 80 milligrams over about five hours, front-loading 30 milligrams in the first hour and then 12.5 milligrams per hour for four more.
ReadyFlow delivers the same 80 milligram dose in a single injection. According to the company, administration time drops from roughly five hours to 10 seconds or less, with symptom relief beginning within an hour.
The practical difference is not only speed. A five-hour wearable pump commits a patient to an afternoon. An autoinjector is a decision that can be made and acted on at the first sign of worsening, which is the scenario the product is designed around.
Patients and prescribers can reach the manufacturer's access and coverage support line at (855) FUROSCIX.
The Hospital Pathway It Is Designed to Intercept
Heart failure is among the leading causes of hospitalization in the United States, and the majority of those admissions are driven by sodium retention and fluid overload rather than by a new cardiac event.
Dan Bensimhon, an advanced heart failure cardiologist in Greensboro, North Carolina, described the pattern to Healio, saying that "two-thirds of patients with HF get admitted only for IV Lasix." He reports serving on the manufacturer's speaker bureau, which readers should weigh alongside the observation.
Hunter Champion of the Emory University Healthcare Network, quoted in the company announcement, framed the same problem from the patient side, describing "worsening fluid overload that can disrupt daily life and lead to ER visits."
The logic is straightforward. If a stronger diuretic dose can be delivered at home when congestion begins to escalate, some admissions that exist only to run an IV might not need to happen. Hospitalization for heart failure also carries its own risks, including hospital-acquired infection and functional decline in older patients, and readmission rates within 30 days are substantial.
That is the hypothesis. It is a reasonable one. It is not what the FDA evaluated.
What the Approval Evidence Shows
This is the part that deserves care, because the gap between what was studied and what is hoped for is wide.
The supplemental application was supported by a Phase 1 study: open-label, single-center, single-dose, randomized, two-way crossover, in 21 healthy volunteers between the ages of 45 and 80. Participants received intravenous furosemide and the autoinjector version in randomized order.
The autoinjector demonstrated bioavailability of 107.3 percent, with a 90 percent confidence interval of 103.9 to 110.8, meeting the standard 80 to 125 percent equivalence window. The company reports equivalent urine output, sodium excretion, and potassium excretion at 6, 8, and 12 hours compared with intravenous furosemide, with a safety profile consistent with oral and intravenous furosemide.
Read plainly: this is a pharmacology bridging study showing the drug gets into the body and produces urine the way the IV version does. It enrolled 21 healthy people, not heart failure patients in decompensation. There is no randomized trial here showing reduced emergency department visits, reduced hospitalizations, or improved survival.
That does not make the approval inappropriate. Bridging an established drug to a new delivery route is exactly what this pathway is for. It does mean that claims about keeping patients out of hospitals are, for now, extrapolation rather than demonstrated outcome.
Who This Is For, and Who It Is Not For
The indication is edema in adults with heart failure or chronic kidney disease. It is a treatment for congestion, not a general heart failure therapy and not a substitute for the medications that improve survival.
The Furoscix label states the product is contraindicated in patients with anuria (producing no urine) and in anyone with a history of hypersensitivity to furosemide, any component of the formulation, or medical adhesives. The label also directs that the product be replaced with oral diuretics as the clinician instructs.
Patient selection is not a formality here. Aggressive diuresis outside a monitored setting can drive potassium and sodium too low, dehydrate a patient, and worsen kidney function. Anyone using this will need a plan for weight monitoring, symptom thresholds, and follow-up laboratory testing, and that plan comes from a cardiologist or nephrologist rather than from a package insert.
One boundary matters more than the rest. This is for worsening congestion managed with a clinician's guidance, not for a respiratory emergency. Severe shortness of breath, chest pain, inability to lie flat, or confusion require emergency care, not a home injection.
Nobody should start, stop or adjust a diuretic based on a news report.
What Happens Next
Commercial availability is expected by the end of August, aimed initially at cardiologists, nephrologists, outpatient heart failure clinics and integrated delivery networks. Insurance coverage will determine how many patients can actually get it, and that is unsettled.
The evidence that would justify the hospital-avoidance claim is a randomized trial with admissions as an endpoint. MedicalDaily will report on any such trial, on coverage decisions, and on real-world safety data as use expands.
The confirmed fact is that the FDA approved a subcutaneous furosemide autoinjector delivering a full 80 milligram dose in under 10 seconds. The people most affected are patients with heart failure or kidney disease who repeatedly cycle through emergency departments for intravenous diuretics. The most reasonable action is a conversation with a cardiologist or nephrologist about whether this fits a specific fluid management plan. The central uncertainty is whether it reduces hospitalizations, which has not been tested.
Frequently Asked Questions
What did the FDA approve? Furoscix ReadyFlow, a furosemide autoinjector delivering an 80 milligram subcutaneous dose in under 10 seconds for edema in adults with heart failure or chronic kidney disease.
How is it different from the existing product? The Furoscix On-body Infusor delivers the same dose over about five hours through a wearable pump. The autoinjector delivers it in a single injection.
Does it prevent hospital admissions? That has not been demonstrated. The approval rested on a pharmacology study in 21 healthy volunteers, not a trial measuring hospitalizations.
Who should not use it? The label lists contraindications including anuria and a history of hypersensitivity to furosemide, formulation components, or medical adhesives.
Can I use it instead of going to the hospital? Not as a substitute for emergency care. Severe breathlessness, chest pain, inability to lie flat, or confusion require emergency evaluation.
When will it be available? The manufacturer expects US availability by the end of August 2026.
Will insurance cover it? Coverage has not been established. The manufacturer operates a support line for access and coverage questions.
